DURHAM, NC--(Marketwired - April 03, 2014) - Patheon, the pharmaceutical services business owned by DPx Holdings, will feature its wide range of API and complex formulation technologies for small molecules and biologics at the upcoming CPhI/ICSE -- Japan conference in Tokyo, Japan.
Tony Pidgeon, senior manager, global science and technology, will present "Strategies for Developing Sterile Dosage Forms" at 16:00 p.m. on April 9, 2014. Also, Anil Kane, Ph.D., executive director of global head of formulation sciences, will present "QbD -- A Contract Manufacturers Perspective and Experience, application to the new Process validation guidance strategy," at 13:45 p.m.
Patheon personnel will be at the upcoming CPhI/ICSE -- Japan conference in Tokyo, Japan from April 9-11, 2014 and available to discuss how the company can actively support pharmaceutical and biotech companies in achieving their objectives for both product development and manufacturing. The company will be exhibiting at Booth J-04 through the duration of the conference. To schedule a meeting in advance send an email to email@example.com.
For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx.
Patheon is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPX business unit, encompasses the combined CMO capabilities and pharmaceutical product development services (PDS), as well as the Biosolutions and Biologics (BIO) business. For more information visit http://www.patheon.com.